Annual Report and full year financial results
Starpharma today released its annual report and financial results for the year ended 30 June 2014.
The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley
Starpharma CEO Jackie Fairley joins The Business’ Presenter Ticky Fullerton to discuss TGA approval of a VivaGel coated condom in depth, revisiting the shorting issue covered prior on the show, the benefits of the announcement to broader Australian innovation, and a business update on Starpharma’s DEP docetaxel drug development.
Glamour UK: Potential Huge News: This New Condom May Be Able to Kill HIV, Herpes, and Other STDs
Glamour UK, a magazine for women with a UK online readership of 3.38 million, covered the announcement that Starpharma had received TGA approval for VivaGel coated condoms.
The Washington Times: HIV-killing condom to soon hit shelves in Australia
The Washington Times’ picked up the announcement that Starpharma and Ansell have received TGA approval of the VivaGel coated condom from The Daily Mail UK.
The Daily Mail: First condom designed to kill HIV "could be available to buy within months"
In an article that goes into a significant amount of scientific detail for a mainstream news publication, the Daily Mail covered the TGA of VivaGel coated condoms announcement.
Elite Daily: The Future of Safe Sex: New Condom in Australia is covered with an HIV-killing lubricant
Elite Daily, a widely read US based publication targeted at generation Y, reported that VivaGel kills up to 99% of HIV and Herpes following the announce TGA approval of VivaGel coated condoms in Australia.
ABC: Starpharma and Ansell get approval for HIV-killing condom
The ABC reported that while condoms are the best method of sexual protection available, they are currently not 100% effective in preventing either pregnancy or sexually transmitted infections and so anything you can do to reduce the number of virus particles by inactivating them with a substance like VivaGel would reduce that overall viral load.
AFR: Virus killing condom to hit shelves
Following the announcement that Starpharma received TGA approval for VivaGel coated condoms in Australia, the AFR reported on the significance of the deal for Australian innovation.
Appendix 4C - Quarterly Cashflow Statement
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2014.
VivaGel® condom receives TGA device certification - Launch preparations to follow
Starpharma today announced achievement of a major milestone with the receipt of Conformity Assessment Certification for the VivaGel® condom by the Australian Therapeutic Goods Administration (TGA). This TGA certification is similar to CE certification of devices (CE Mark) in Europe.